User Review
( votes)
2022 has been a tough year for the markets. But Biotech has been hit especially hard. Funding decreased by almost 60% from its 2021 peak. And things will probably get worse before they get better. With recession expectations high among C-suite executives, and more interest rate increases expected in July, the financing environment for the rest of the year will be tough. While market fundamentals are still intact, Biotech startups must compete harder for funding and devise new strategies to manage risk.
